These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 1611136

  • 1. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosén I, Sönksen P.
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [Abstract] [Full Text] [Related]

  • 2. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P, Attali JR, Gagant S.
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
    Boland OM, Blackwell CC, Clarke BF, Ewing DJ.
    Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA, Prashar A, Zhang WX, Chakrabarti S, Greene DA.
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [Abstract] [Full Text] [Related]

  • 7. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS, Williams G, Ghatei MA, Hetreed AH, Mather HM, Bloom SR.
    Diabete Metab; 1990 May; 16(4):296-302. PubMed ID: 2125013
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V, Buchanan RA.
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B.
    J Diabetes Complications; 1993 Jan; 7(3):170-8. PubMed ID: 8343611
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
    Price DE, Alani SM, Wales JK.
    Diabetes Care; 1991 May; 14(5):411-3. PubMed ID: 1905621
    [Abstract] [Full Text] [Related]

  • 16. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
    Cameron NE, Cotter MA, Robertson S.
    Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.